文献速递产科麻醉区域麻醉与超声

剖宫产麻醉:鞘内布比卡因单用不劣于布比卡因复合芬太尼的随机双盲非劣效试验

Intrathecal bupivacaine versus bupivacaine plus fentanyl for anaesthesia for Caesarean delivery: a randomised double-blind noninferiority trial.
PubMed 文献 · Br J Anaesth · 2025-11-13

本研究为随机双盲非劣效试验,纳入626例行择期剖宫产联合脊髓-硬膜外麻醉的产妇,比较鞘内重比重布比卡因10.75 mg与布比卡因9.0 mg复合芬太尼15 μg的有效麻醉率。结果显示两组有效麻醉率分别为94.4%和92.5%,绝对差1.9%(95%CI -2.0%至5.9%),非劣效成立(P=0.003);布比卡因复合芬太尼组瘙痒发生率更高(7.2% vs 0.7%,P<0.001)。

要点

  • 鞘内布比卡因10.75 mg单用不劣于布比卡因9.0 mg复合芬太尼15 μg。
  • 单用布比卡因组瘙痒发生率显著低于复合芬太尼组。
  • 当不希望或无法加用芬太尼时,可考虑单用布比卡因。

核心结论

  • 在剖宫产脊髓麻醉中,鞘内单用较高剂量布比卡因10.75 mg在有效麻醉方面不劣于布比卡因9.0 mg复合芬太尼15 μg。

研究设计与样本

  • 随机双盲非劣效试验,纳入626例行择期剖宫产联合脊髓-硬膜外麻醉的产妇。
  • 主要结局为有效麻醉,定义为10分钟内达T5感觉阻滞且前45分钟内无需要治疗的术中疼痛。
  • 非劣效界值为绝对差异5%。

主要发现

  • 有效麻醉率:布比卡因组94.4%(95%CI 91.1-96.7%),复合芬太尼组92.5%(95%CI 88.9-95.2%)。
  • 两组绝对差异1.9%(95%CI -2.0%至5.9%),非劣效成立(P=0.003)。
  • 瘙痒发生率:复合芬太尼组7.2%,单用布比卡因组0.7%(P<0.001)。
  • 其他次要结局两组间无差异。

关键数值与推荐

  • 鞘内重比重布比卡因10.75 mg单用与布比卡因9.0 mg复合芬太尼15 μg相比,有效麻醉率绝对差1.9%(95%CI -2.0%至5.9%),非劣效界值5%。

临床怎么用

  • 当不希望或无法在鞘内加用芬太尼时,可考虑单用布比卡因10.75 mg进行剖宫产脊髓麻醉。
  • 单用布比卡因可降低瘙痒发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fentanyl is commonly mixed with bupivacaine for spinal anaesthesia for Caesarean delivery. However, fentanyl has potential disadvantages. We hypothesised that simply increasing the bupivacaine dose would be at least as effective as adding fentanyl. METHODS: We performed a randomised, double-blinded trial in 626 women having elective Caesarean delivery under combined spinal-epidural anaesthesia to determine whether intrathecal hyperbaric bupivacaine 10.75 mg is noninferior to bupivacaine 9.0 mg plus fentanyl 15 μg for the primary outcome of effective anaesthesia, defined as T5 sensory block within 10 min and no intraoperative pain requiring treatment within the first 45 min. The chosen noninferiority margin was an absolute difference of 5%. Secondary outcomes included the incidences of intraoperative pain, nausea and vomiting, hypotension, and pruritus. RESULTS: Effective anaesthesia was achieved in 94.4% (95% confidence interval [CI], 91.1-96.7%) of patients with bupivacaine vs 92.5% (95% CI, 88.9-95.2%) with bupivacaine plus fentanyl. The absolute difference between groups was 1.9% (95% CI, -2.0% to 5.9%); because the lower confidence limit is greater than the noninferiority margin, noninferiority of bupivacaine was demonstrated (P=0.003). The incidence of pruritus was greater with bupivacaine plus fentanyl (7.2%) vs bupivacaine alone (0.7%) (P<0.001). There was no difference between groups for other secondary outcomes. CONCLUSIONS: Under the condition of this study, use of a higher dose of intrathecal bupivacaine was noninferior to bupivacaine plus fentanyl for providing effective anaesthesia for Caesarean delivery. Use of bupivacaine alone for spinal anaesthesia for Caesarean delivery can be considered when adding fentanyl is not desired or not feasible. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2400080830).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Sun LH, Jiao CC, Wu H, et al. Intrathecal bupivacaine versus bupivacaine plus fentanyl for anaesthesia for Caesarean delivery: a randomised double-blind noninferiority trial. Br J Anaesth. 2025. PMID: 41233195. doi:10.1016/j.bja.2025.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。